Benjamin Landry Sells 13,827 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares of the company’s stock, valued at $729,988.35. This represents a 7.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Benjamin Landry also recently made the following trade(s):

• On Monday, January 6th, Benjamin Landry sold 2,500 shares of Health Catalyst stock. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00.

Health Catalyst Stock Up 5.0 %

Shares of NASDAQ HCAT opened at $4.17 on Wednesday. The firm’s 50-day moving average price is $5.62 and its 200-day moving average price is $7.11. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $292.78 million, a price-to-earnings ratio of -3.09 and a beta of 1.41. Health Catalyst, Inc. has a 12-month low of $3.76 and a 12-month high of $9.24.

Institutional Trading of Health Catalyst

Several hedge funds have recently made changes to their positions in HCAT. First Light Asset Management LLC raised its position in shares of Health Catalyst by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock valued at $37,055,000 after buying an additional 944,631 shares in the last quarter. Alyeska Investment Group L.P. raised its position in Health Catalyst by 74.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after purchasing an additional 861,150 shares during the period. Fred Alger Management LLC purchased a new stake in Health Catalyst in the 3rd quarter worth about $6,858,000. Portolan Capital Management LLC purchased a new stake in Health Catalyst in the 3rd quarter worth about $5,402,000. Finally, Kennedy Capital Management LLC raised its position in Health Catalyst by 42.7% in the 4th quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock worth $13,369,000 after purchasing an additional 565,445 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HCAT has been the subject of several recent analyst reports. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, January 8th. Piper Sandler decreased their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Stifel Nicolaus decreased their price target on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. Royal Bank of Canada decreased their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 27th. Finally, Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Health Catalyst presently has an average rating of “Moderate Buy” and an average target price of $9.27.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.